Register for our free email digests:
Latest From Yuhan Corp.
Local firm Yuhan is taking over from Merck as marketing partner in South Korea for Samsung Bioepis’ biosimilars amid speculation that weak sales of infliximab and etanercept may have triggered the realignment. Samsung Bioepis and Merck's broader partnership, however, remains intact.
AbClon has made a strong debut on the Kosdaq market with investors backing the innovative antibody drug firm in a year where IPOs by South Korean novel drug developers have been generally scarce.
At year's end the French pharma also announced a restructuring of its broad diabetes collaboration with South Korea’s Hanmi. In a deal involving two other French companies, OSE out-licensed global development and commercial rights to an IL-7 antagonist to Servier.
For the South Korean pharma industry, 2016 was largely about major global advances for a wide range of biosimilars, accompanied but some setbacks in the area of novel drug development.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Metabolic Disorders
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Yuhan Corp.
- Senior Management
- Jung Hee Lee, Pres. & CEO
- Contact Info
Phone: 2 828 0181
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.